Similar articles for PMID: 29275134

Year	Number of Results
2002	2
2004	1
2006	1
2007	1
2008	2
2009	3
2010	3
2011	6
2012	3
2013	8
2014	10
2015	18
2016	13
2017	24
2018	22
2019	17
2020	18
2021	26
2022	14
2023	6
2024	1

1

Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.

Khouri C, Lepelley M, Roustit M, Montastruc F, Humbert M, Cracowski JL. Khouri C, et al. Chest. 2018 Jul;154(1):136-147. doi: 10.1016/j.chest.2017.12.008. Epub 2017 Dec 21. Chest. 2018. PMID: 29275134 Review.

2

Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.

Hoeper MM, Klinger JR, Benza RL, Simonneau G, Langleben D, Naeije R, Corris PA. Hoeper MM, et al. Respir Med. 2017 Jan;122 Suppl 1:S18-S22. doi: 10.1016/j.rmed.2016.11.001. Epub 2016 Nov 5. Respir Med. 2017. PMID: 27887774 Free article. Clinical Trial.

3

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.

Gall H, Vachiéry JL, Tanabe N, Halank M, Orozco-Levi M, Mielniczuk L, Chang M, Vogtländer K, Grünig E. Gall H, et al. Lung. 2018 Jun;196(3):305-312. doi: 10.1007/s00408-018-0100-3. Epub 2018 Feb 22. Lung. 2018. PMID: 29470642 Free PMC article.

4

Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.

Kimura M, Tamura Y, Takei M, Yamamoto T, Ono T, Fujita J, Kataoka M, Kuwana M, Satoh T, Fukuda K. Kimura M, et al. BMC Pulm Med. 2015 May 14;15:62. doi: 10.1186/s12890-015-0037-8. BMC Pulm Med. 2015. PMID: 25971443 Free PMC article.

5

Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.

Yamamoto K, Tanabe N, Suda R, Sasaki A, Matsumura A, Ema R, Kasai H, Kato F, Sekine A, Nishimura R, Jujo T, Sugiura T, Shigeta A, Sakao S, Tatsumi K. Yamamoto K, et al. Respir Investig. 2017 Jul;55(4):270-275. doi: 10.1016/j.resinv.2017.04.004. Epub 2017 Jun 19. Respir Investig. 2017. PMID: 28705306

6

Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.

Triposkiadis F, Xanthopoulos A, Skoularigis J, Starling RC. Triposkiadis F, et al. Heart Fail Rev. 2022 Nov;27(6):1991-2003. doi: 10.1007/s10741-022-10239-5. Epub 2022 Apr 18. Heart Fail Rev. 2022. PMID: 35437713 Review.

7

Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.

Pradhan K, Sydykov A, Tian X, Mamazhakypov A, Neupane B, Luitel H, Weissmann N, Seeger W, Grimminger F, Kretschmer A, Stasch JP, Ghofrani HA, Schermuly RT. Pradhan K, et al. Int J Cardiol. 2016 Aug 1;216:85-91. doi: 10.1016/j.ijcard.2016.04.098. Epub 2016 Apr 16. Int J Cardiol. 2016. PMID: 27140341

8

Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study.

Jaffey JA, Leach SB, Kong LR, Wiggen KE, Bender SB, Reinero CR. Jaffey JA, et al. J Vet Cardiol. 2019 Aug;24:7-19. doi: 10.1016/j.jvc.2019.05.001. Epub 2019 May 11. J Vet Cardiol. 2019. PMID: 31405557 Free PMC article.

9

Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts.

Sabri MR, Bigdelian H, Hosseinzadeh M, Ahmadi A, Ghaderian M, Shoja M. Sabri MR, et al. Cardiol Young. 2017 Nov;27(9):1686-1693. doi: 10.1017/S1047951117000981. Cardiol Young. 2017. PMID: 28994364 Clinical Trial.

10

[Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat].

Martynyuk TV, Shmalts AA, Gorbachevsky SV, Chazova IE. Martynyuk TV, et al. Ter Arkh. 2021 Sep 15;93(9):1117-1124. doi: 10.26442/00403660.2021.09.201014. Ter Arkh. 2021. PMID: 36286873 Russian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

171 results

Results by year